UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                -----------------
                                    FORM 8-K
                                -----------------

                                 CURRENT REPORT
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                        Date of report: January 30, 2007


                           THERAGENICS CORPORATION(R)
               (Exact name of registrant as specified in charter)



        Delaware                   000-15443                58-1528626
(State of incorporation)   (Commission File Number)        (IRS Employer
                                                        Identification No.)
                     5203 Bristol Industrial Way
                        Buford, Georgia 30518
         (Address of principal executive offices / Zip Code)


                           (770) 271-0233
        (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[_]      Written communications pursuant to Rule 425 under the Securities Act
         (17 CFR 230.425)

[_]      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
         CFR 240.14a-12)

[_]      Pre-commencement communications pursuant to Rule 14d-2(b) under the
         Exchange Act (17 CFR 240.14d-2(b))

[_]      Pre-commencement communications pursuant to Rule 13e-4(c) under the
         Exchange Act (17 CFR 240.13e-4(c))




Item 2.02. Results of Operations and Financial Condition.

        On January 30, 2007, Theragenics Corporation (the "Company") issued a
press release regarding its consolidated financial results for the quarter and
year ended December 31, 2006. The Company's press release is furnished as
Exhibit 99.1 to this Current Report on Form 8-K.

        The information in this Current Report on Form 8-K and the Exhibit
attached hereto shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933 or the Exchange Act, regardless of
any general incorporation language in such filing.




                                   SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                      Theragenics Corporation

                                      (Registrant)

                                      Dated: January 30, 2007

                                      By: /s/ M. Christine Jacobs
                                      ---------------------------
                                      M. Christine Jacobs
                                      Chief Executive Officer


                                  EXHIBIT INDEX

Exhibit No.          Description
- -----------          -----------
99.1                 Press Release, dated January 30, 2007
                     of Theragenics Corporation.